Abstract
This spring, five years have passed since the first presentation and publication of the results of ONTARGET study, which - among other things - changed the indication for telmisartan. The study was first presented at the Congress of American College of Cardiology in Chicago at the end of March 2008 and published simultaneously in the New England Journal of Medicine.
The study examined 25,577 patients with ischemic heart disease or peripheral arterial disease or cerebrovascular disease (following strokes or TIA), or diabetes mellitus and organ damage. The study was conducted in 40 countries (including the Czech Republic) in 733 centers.